Inotiv, Inc. (NOTV)
USD 1.55
(3.33%)
USD 1.55
(3.33%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 588.04 Million USD | -2.5% |
| 2022 | 603.13 Million USD | 178.29% |
| 2021 | 216.72 Million USD | 301.37% |
| 2020 | 53.99 Million USD | 72.68% |
| 2019 | 31.27 Million USD | 53.4% |
| 2018 | 20.38 Million USD | 70.58% |
| 2017 | 11.95 Million USD | -12.65% |
| 2016 | 13.68 Million USD | 4.46% |
| 2015 | 13.09 Million USD | -8.01% |
| 2014 | 14.23 Million USD | -11.77% |
| 2013 | 16.13 Million USD | -7.17% |
| 2012 | 17.38 Million USD | 3.73% |
| 2011 | 16.76 Million USD | -12.14% |
| 2010 | 19.07 Million USD | -2.0% |
| 2009 | 19.46 Million USD | -13.69% |
| 2008 | 22.55 Million USD | -3.96% |
| 2007 | 23.48 Million USD | -5.92% |
| 2006 | 24.96 Million USD | -11.62% |
| 2005 | 28.24 Million USD | 3.16% |
| 2004 | 27.37 Million USD | 8.38% |
| 2003 | 25.25 Million USD | 73.43% |
| 2002 | 14.56 Million USD | 43.54% |
| 2001 | 10.14 Million USD | -4.29% |
| 2000 | 10.6 Million USD | 19.11% |
| 1999 | 8.9 Million USD | 61.82% |
| 1998 | 5.5 Million USD | -38.89% |
| 1997 | 9 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 581.34 Million USD | -1.14% |
| 2024 Q3 | 592.48 Million USD | -2.59% |
| 2024 Q2 | 608.21 Million USD | 4.62% |
| 2023 FY | 588.04 Million USD | -2.5% |
| 2023 Q4 | 588.04 Million USD | 1.47% |
| 2023 Q3 | 579.5 Million USD | -2.77% |
| 2023 Q2 | 596.03 Million USD | 0.81% |
| 2023 Q1 | 591.25 Million USD | -1.97% |
| 2022 Q1 | 413.48 Million USD | 90.78% |
| 2022 Q3 | 554.14 Million USD | 6.16% |
| 2022 Q4 | 603.13 Million USD | 8.84% |
| 2022 FY | 603.13 Million USD | 178.29% |
| 2022 Q2 | 522.01 Million USD | 26.25% |
| 2021 Q4 | 216.72 Million USD | 161.18% |
| 2021 FY | 216.72 Million USD | 301.37% |
| 2021 Q3 | 82.97 Million USD | 44.32% |
| 2021 Q2 | 57.49 Million USD | 3.89% |
| 2021 Q1 | 55.34 Million USD | 2.49% |
| 2020 Q3 | 54.49 Million USD | 5.31% |
| 2020 Q1 | 50.54 Million USD | 61.65% |
| 2020 Q2 | 51.74 Million USD | 2.36% |
| 2020 Q4 | 53.99 Million USD | -0.91% |
| 2020 FY | 53.99 Million USD | 72.68% |
| 2019 FY | 31.27 Million USD | 53.4% |
| 2019 Q4 | 31.27 Million USD | 10.46% |
| 2019 Q3 | 28.31 Million USD | 31.72% |
| 2019 Q2 | 21.49 Million USD | 6.64% |
| 2019 Q1 | 20.15 Million USD | -1.12% |
| 2018 Q4 | 20.38 Million USD | 57.02% |
| 2018 FY | 20.38 Million USD | 70.58% |
| 2018 Q3 | 12.98 Million USD | 10.19% |
| 2018 Q2 | 11.78 Million USD | -1.83% |
| 2018 Q1 | 12 Million USD | 0.44% |
| 2017 Q2 | 13.05 Million USD | -4.08% |
| 2017 FY | 11.95 Million USD | -12.65% |
| 2017 Q1 | 13.61 Million USD | -0.5% |
| 2017 Q3 | 12.16 Million USD | -6.81% |
| 2017 Q4 | 11.95 Million USD | -1.79% |
| 2016 Q2 | 13.13 Million USD | 13.1% |
| 2016 Q1 | 11.61 Million USD | -11.32% |
| 2016 Q4 | 13.68 Million USD | -2.58% |
| 2016 FY | 13.68 Million USD | 4.46% |
| 2016 Q3 | 14.04 Million USD | 6.91% |
| 2015 Q2 | 13.02 Million USD | -6.77% |
| 2015 Q4 | 13.09 Million USD | 9.76% |
| 2015 Q1 | 13.97 Million USD | -1.88% |
| 2015 Q3 | 11.93 Million USD | -8.38% |
| 2015 FY | 13.09 Million USD | -8.01% |
| 2014 Q2 | 14.62 Million USD | -4.29% |
| 2014 Q3 | 15.01 Million USD | 2.7% |
| 2014 Q4 | 14.23 Million USD | -5.19% |
| 2014 Q1 | 15.27 Million USD | -5.32% |
| 2014 FY | 14.23 Million USD | -11.77% |
| 2013 Q4 | 16.13 Million USD | 7.85% |
| 2013 FY | 16.13 Million USD | -7.17% |
| 2013 Q3 | 14.96 Million USD | -0.23% |
| 2013 Q2 | 14.99 Million USD | -1.53% |
| 2013 Q1 | 15.23 Million USD | -12.38% |
| 2012 Q2 | 17.28 Million USD | -1.31% |
| 2012 Q4 | 17.38 Million USD | 2.08% |
| 2012 Q3 | 17.03 Million USD | -1.46% |
| 2012 FY | 17.38 Million USD | 3.73% |
| 2012 Q1 | 17.51 Million USD | 4.49% |
| 2011 Q4 | 16.76 Million USD | -7.18% |
| 2011 Q1 | 18.04 Million USD | -5.41% |
| 2011 Q2 | 17.38 Million USD | -3.64% |
| 2011 Q3 | 18.05 Million USD | 3.85% |
| 2011 FY | 16.76 Million USD | -12.14% |
| 2010 Q3 | 19.15 Million USD | -3.48% |
| 2010 FY | 19.07 Million USD | -2.0% |
| 2010 Q2 | 19.84 Million USD | 7.13% |
| 2010 Q1 | 18.51 Million USD | -4.86% |
| 2010 Q4 | 19.07 Million USD | -0.39% |
| 2009 Q4 | 19.46 Million USD | -2.52% |
| 2009 Q2 | 20.4 Million USD | 2.59% |
| 2009 FY | 19.46 Million USD | -13.69% |
| 2009 Q1 | 19.89 Million USD | -11.79% |
| 2009 Q3 | 19.96 Million USD | -2.16% |
| 2008 Q2 | 21.93 Million USD | 5.17% |
| 2008 FY | 22.55 Million USD | -3.96% |
| 2008 Q1 | 20.85 Million USD | -11.19% |
| 2008 Q3 | 22.61 Million USD | 3.1% |
| 2008 Q4 | 22.55 Million USD | -0.28% |
| 2007 Q2 | 23.32 Million USD | -1.1% |
| 2007 Q4 | 23.48 Million USD | 5.28% |
| 2007 Q3 | 22.3 Million USD | -4.39% |
| 2007 FY | 23.48 Million USD | -5.92% |
| 2007 Q1 | 23.58 Million USD | -5.5% |
| 2006 Q3 | 25.63 Million USD | -2.19% |
| 2006 Q4 | 24.96 Million USD | -2.62% |
| 2006 Q1 | 29.53 Million USD | 4.59% |
| 2006 Q2 | 26.2 Million USD | -11.27% |
| 2006 FY | 24.96 Million USD | -11.62% |
| 2005 Q4 | 28.24 Million USD | 0.98% |
| 2005 Q2 | 25.52 Million USD | -13.14% |
| 2005 Q1 | 29.38 Million USD | 7.34% |
| 2005 Q3 | 27.96 Million USD | 9.57% |
| 2005 FY | 28.24 Million USD | 3.16% |
| 2004 Q3 | 27.22 Million USD | -0.75% |
| 2004 FY | 27.37 Million USD | 8.38% |
| 2004 Q4 | 27.37 Million USD | 0.54% |
| 2004 Q1 | 27.33 Million USD | 8.22% |
| 2004 Q2 | 27.43 Million USD | 0.37% |
| 2003 Q1 | 19.93 Million USD | 36.88% |
| 2003 Q4 | 25.25 Million USD | 5.35% |
| 2003 FY | 25.25 Million USD | 73.43% |
| 2003 Q3 | 23.97 Million USD | 24.64% |
| 2003 Q2 | 19.23 Million USD | -3.51% |
| 2002 Q1 | 10.1 Million USD | -0.42% |
| 2002 Q3 | 12.45 Million USD | 7.24% |
| 2002 Q4 | 14.56 Million USD | 16.91% |
| 2002 FY | 14.56 Million USD | 43.54% |
| 2002 Q2 | 11.61 Million USD | 14.97% |
| 2001 Q1 | 10.56 Million USD | -0.36% |
| 2001 Q4 | 10.14 Million USD | 9.32% |
| 2001 FY | 10.14 Million USD | -4.29% |
| 2001 Q2 | 11.33 Million USD | 7.31% |
| 2001 Q3 | 9.28 Million USD | -18.12% |
| 2000 Q1 | 8.8 Million USD | -1.12% |
| 2000 Q2 | 9.3 Million USD | 5.72% |
| 2000 Q3 | 9.47 Million USD | 1.82% |
| 2000 Q4 | 10.6 Million USD | 11.92% |
| 2000 FY | 10.6 Million USD | 19.11% |
| 1999 Q3 | 7.8 Million USD | 11.43% |
| 1999 Q4 | 8.9 Million USD | 14.1% |
| 1999 FY | 8.9 Million USD | 61.82% |
| 1999 Q1 | 5.3 Million USD | -3.64% |
| 1999 Q2 | 7 Million USD | 32.08% |
| 1998 Q3 | 3.5 Million USD | 2.94% |
| 1998 FY | 5.5 Million USD | -38.89% |
| 1998 Q2 | 3.4 Million USD | -8.11% |
| 1998 Q1 | 3.7 Million USD | -59.12% |
| 1998 Q4 | 5.5 Million USD | 57.14% |
| 1997 FY | 9 Million USD | 0.0% |
| 1997 Q4 | 9.05 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aspira Women's Health Inc. | 8.62 Million USD | -6716.274% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -17368.453% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | -10408.836% |
| Standard BioTools Inc. | 159.86 Million USD | -267.835% |
| Prenetics Global Limited | 44.01 Million USD | -1236.052% |
| Neuronetics, Inc. | 81.64 Million USD | -620.275% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -2612.987% |
| Castle Biosciences, Inc. | 86.54 Million USD | -579.485% |
| Psychemedics Corporation | 6.59 Million USD | -8812.398% |
| RadNet, Inc. | 2.07 Billion USD | 71.638% |
| Exact Sciences Corporation | 3.32 Billion USD | 82.32% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | 66.878% |
| iSpecimen Inc. | 6.07 Million USD | -9574.798% |
| OpGen, Inc. | 13.44 Million USD | -4274.042% |
| Exagen Inc. | 34.25 Million USD | -1616.905% |
| Bionano Genomics, Inc. | 118.24 Million USD | -397.298% |
| CareDx, Inc | 223.28 Million USD | -163.356% |
| Check-Cap Ltd. | 1.33 Million USD | -44113.534% |
| Twist Bioscience Corporation | 152.97 Million USD | -284.413% |
| Guardant Health, Inc. | 1.62 Billion USD | 63.874% |
| Biodesix, Inc. | 94.51 Million USD | -522.159% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -33657.745% |
| Precipio, Inc. | 3.67 Million USD | -15914.161% |
| Natera, Inc. | 691.79 Million USD | 14.998% |
| Fulgent Genetics, Inc. | 139.82 Million USD | -320.56% |
| Sera Prognostics, Inc. | 25.28 Million USD | -2225.832% |
| 23andMe Holding Co. | 206.64 Million USD | -184.563% |
| OPKO Health, Inc. | 622.47 Million USD | 5.533% |
| Personalis, Inc. | 95.65 Million USD | -514.732% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -1361.841% |
| Applied DNA Sciences, Inc. | 8.77 Million USD | -6598.131% |
| T2 Biosystems, Inc. | 62.83 Million USD | -835.878% |
| Neogen Corporation | 1.44 Billion USD | 59.164% |
| Myriad Genetics, Inc. | 312.9 Million USD | -87.932% |
| ICON Public Limited Company | 7.74 Billion USD | 92.412% |
| NeoGenomics, Inc. | 739.69 Million USD | 20.502% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -2612.987% |
| MDxHealth SA | 121.92 Million USD | -382.3% |
| Prenetics Global Limited | 44.01 Million USD | -1236.052% |
| Illumina, Inc. | 4.36 Billion USD | 86.531% |
| DarioHealth Corp. | 38.24 Million USD | -1437.56% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -53594.584% |
| Medpace Holdings, Inc. | 1.09 Billion USD | 46.438% |
| Mainz Biomed B.V. | 12.15 Million USD | -4735.934% |
| Trinity Biotech plc | 83.38 Million USD | -605.219% |
| Sotera Health Company | 2.68 Billion USD | 78.113% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -17368.453% |